AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Sangamo Therapeutics Appoints James R. Meyers to Its Board of Directors

November 26, 2019 GMT

BRISBANE, Calif.--(BUSINESS WIRE)--Nov 26, 2019--

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of James R. Meyers, an accomplished pharmaceutical executive with three decades of commercial experience, to the Company’s Board of Directors.

“We are pleased that Jim has joined the Sangamo Board of Directors,” said Sandy Macrae, Chief Executive Officer of Sangamo. “We believe that Jim’s organizational development experience will provide great benefit to Sangamo as we continue to grow, and that his commercial, public policy, and pricing and access expertise will support our later stage programs through to registration and help get our medicines to patients in need.”

Mr. Meyers has over 30 years of commercial leadership experience in the biotechnology industry and worked at Gilead from 1996 until his retirement in February 2018. Most recently, he served as Gilead’s Executive Vice President of Worldwide Commercial Operations, where he was responsible for global commercial activities, including pricing and market access in North America, Europe, Middle East, Australia and Japan. At Gilead, he successfully led several important product launches in the HIV and hepatitis C therapeutic areas. Prior to Gilead, Mr. Meyers held positions of increasing responsibility with Zeneca Pharmaceuticals and Astra USA. He currently serves on the Board of Directors of two public companies, Arbutus Biopharma Corp. and CytomX Therapeutics, and remains an active advisor to several major biopharmaceutical companies. Mr. Meyers holds a B.S. in Economics from Boston College.

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit www.sangamo.com.

Forward Looking Statements

This press release contains or refers to forward-looking statements regarding Sangamo’s current expectations. These forward-looking statements include, without limitation, statements regarding the potential benefits of cell therapy, the Company’s ability to develop and commercialize product candidates to address genetic diseases with the Company’s proprietary technologies and the timing of commencement or next stages of such programs and the anticipated benefits therefrom. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo’s operations and business environments. These risks and uncertainties are described more fully in Sangamo’s Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the Securities and Exchange Commission on March 1, 2019 and Sangamo’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 that it filed on November 6, 2019. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191126005294/en/

CONTACT: Investor Relations – Global

McDavid Stilwell

510-970-6000, x219

mstilwell@sangamo.com Media Inquiries – Global

Aron Feingold

510-970-6000, x421

afeingold@sangamo.com Investor Relations and Media Inquiries – European Union & United Kingdom

Caroline Courme

33 4 97 21 27 27

ccourme@sangamo.com

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES STEM CELLS GENETICS CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Sangamo Therapeutics, Inc.

Copyright Business Wire 2019.

PUB: 11/26/2019 08:30 AM/DISC: 11/26/2019 08:30 AM

http://www.businesswire.com/news/home/20191126005294/en